SeneSIQ · cellular-senescence & senolytics evidence reference

The compiled studies do not establish human lifespan benefit. Lifespan extension in this collection comes from animal studies. The compiled human studies include small pilots and early-phase studies with feasibility, biomarker, or disease endpoints — including one failed Phase 2. Every intervention page shows this plainly.

Interventions

Dasatinib + Quercetin (D+Q)

Human lifespan benefit: not established in this collection

Human lifespan benefit: not established in this collection

Navitoclax (ABT-263)

Human lifespan benefit: not established in this collection

Human lifespan benefit: not established in this collection

Human lifespan benefit: not established in this collection

Human lifespan benefit: not established in this collection

Genetic senescent-cell clearance (INK-ATTAC / p16 ablation)

Human lifespan benefit: not established in this collection

Study records

Senolytics in idiopathic pulmonary fibrosis: first-in-human, open-label pilot (Justice et al., 2019)

Senolytics decrease senescent cells in humans: D+Q in diabetic kidney disease (Hickson et al., 2019)

Senolytic therapy in mild Alzheimer's disease (SToMP-AD): open-label CNS-penetration pilot (Gonzales et al., 2023)

Fisetin is a senotherapeutic that extends health and lifespan (Yousefzadeh et al., 2018)

Fisetin for frailty and inflammation in older adults (AFFIRM / AFFIRM-LITE) — ongoing

Identification of navitoclax as a senolytic targeting the Bcl-2 family (Zhu et al., 2016)

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice (Chang et al., 2016)

UBX0101 Phase 2 in painful knee osteoarthritis — failed primary endpoint (UNITY Biotechnology, 2020)

Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders (Baker et al., 2011)

Naturally occurring p16Ink4a-positive cells shorten healthy lifespan (Baker et al., 2016)

Mechanisms

Cellular senescence

p16INK4a (CDKN2A)

Arrest effector / biomarker

p21CIP1 (CDKN1A)

Arrest effector

p53 / MDM2 axis

Arrest control node

SASP (senescence-associated secretory phenotype)

Secretory phenotype

Bcl-2 / Bcl-xL survival network (SCAPs)

Survival / anti-apoptotic node

Senescence-associated beta-galactosidase (SA-beta-gal)

Biomarker (assay)

Senolytics vs senomorphics

Framing / taxonomy

Senescent-cell burden and aging

Causal-evidence concept

Evidence tiers

Tier	Label	Note
1	Human lifespan-endpoint RCT	Randomized human lifespan endpoint. No lifespan benefit established by the studies compiled here.
2	Human RCT — disease or biomarker endpoint	Randomized, but endpoint is a disease score or biomarker, not lifespan.
3	Human open-label pilot (feasibility / biomarker)	Small, non-randomized; feasibility, tolerability, or senescent-cell biomarker change.
4	Human observational / mechanistic	Cohort, cross-sectional, or ex-vivo human tissue.
5	Animal lifespan study	Median or maximum lifespan change in an animal model. Replication across independent publications is not required at this tier and is not implied by it; where a result has been replicated, the record says so explicitly.
6	Animal healthspan / mechanism study	Function, pathology, or senescent-cell clearance in an animal model; not a lifespan endpoint.
7	In vitro / ex vivo	Cell-culture senolysis or mechanism; no whole-organism outcome.